RenovoRx Q2 Revenue Surges 61% Sequentially, Guidance Raised, TIGeR-PaC Fully Enrolled; Thesis Strengthens but Financing Risk Remains

What happened

RenovoRx reported record Q2 2026 revenue with 61% sequential growth, driven by accelerating RenovoCath adoption, and raised full-year guidance to $3.75M-$4.25M. The company also announced the first clinical use of RenovoCath in a sarcoma patient, expanding its addressable market beyond pancreatic cancer. Importantly, the Phase III TIGeR-PaC trial reached full enrollment, with completion expected in H1 2027 and topline data in H2 2027. This directly addresses two key near-term catalysts identified in prior analysis: confirmation of enrollment closure and sustained sequential revenue growth. However, the release omits detailed financials and active center count, leaving open questions about cash burn and center activation trajectory.

Implication

The Q2 results confirm that the commercialization strategy is executing, with revenue growth accelerating and the trial milestone achieved; this reduces downside risk from a broken growth narrative. However, RNXT remains a pre-profit company with a $3.7M quarterly operating cash burn and a liquidity statement only covering the next 12 months, so dilution risk persists. The raised guidance to $3.75M-$4.25M implies Q3 and Q4 revenue must average roughly $1.1M-$1.35M per quarter, which is achievable but dependent on continued center activations and utilization; management must disclose active center count and any trial-site conversions to substantiate the ramp. The sarcoma use case expands the TAM, but its contribution in the near term is likely minimal and should not be a primary valuation driver. Overall, the stock is likely to re-rate modestly on this news, but the WAIT rating remains appropriate until we see Q3 results and clearer evidence of a path to 36 active centers without an emergency capital raise.

Thesis delta

The prior WAIT thesis was contingent on confirmation of TIGeR-PaC enrollment closure and sustained sequential revenue growth; both have now been achieved. This shifts the risk profile from 'unproven execution' to 'scaling validation,' and the bull case (revenue $4.0M and 36 centers) is now more plausible. However, the thesis is not yet upgraded because the company has not disclosed Q2 revenue in dollars, active center count, or cash runway extension, so the financing overhang remains.